April 4, 2019

A joint HMA and EMA taskforce analyzes the use of big data for the evaluation and monitoring of medicines

The Joint Big Data taskforce (“Taskforce”) between the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) was formed to describe the big data landscape from a regulatory perspective in order to ensure that the EU regulatory system has the capability and capacity to guide, analyze and interpret this data. Its work aims to facilitate the use of such data for the process of evaluation and monitoring of medicines by the regulatory authorities, analyzing the risk-benefit of medicinal products during their lifetime.

On February 15, 2019, the Taskforce issued a report with a number of recommendations and associated actions that set out needs to be addressed, although the mechanisms by which these may be achieved require further focused work over the coming year. Since the term “big data” is widely used but lacks a commonly accepted definition, this Report provides a definition of big data as «extremely large datasets which may be complex, multi-dimensional, unstructured and heterogeneous, which are accumulating rapidly and which may be analyzed computationally to reveal patterns, trends, and associations».

In particular, the Taskforce takes into account the considerable amount of data deriving from wearable devices, electronic health records, social media and clinical trials and assesses how to utilize it for regulatory purposes. The description carried out by the Taskforce focused on six data subgroups: genomics, bioanalytical ‘omics, clinical trials, observational data, data on spontaneous adverse drug reactions and social media and m-health data.

For instance, with regard to data standardization, the Taskforce suggests promoting the use of global, harmonized and comprehensive standards to facilitate interoperability of data. Secondly, with respect to data quality, the Taskforce specifies that characterization of data quality across multiple data sources is essential in order to fully understand the reliability of the evidence. Additionally, it recommends the development of timely, efficient and sustainable frameworks for data sharing and access, as well as to further support mechanisms to promote a culture of data sharing.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the Life Sciences-Healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and Venture Capital transactions.

Close
October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Search
Follow us on
Follow us on